PureTech Health (PRTC) Stock Forecast, Price Target & Predictions
PRTC Stock Forecast
PureTech Health stock forecast is as follows: an average price target of $57.00 (represents a 173.64% upside from PRTC’s last price of $20.83) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PRTC Price Target
The average price target for PureTech Health (PRTC) is $57.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $44.00. This represents a potential 173.64% upside from PRTC's last price of $20.83.
PRTC Analyst Ratings
According to 2 Wall Street analysts, PureTech Health's rating consensus is 'Buy'. The analyst rating breakdown for PRTC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
PureTech Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 25, 2022 | Edward Tenthoff | Piper Sandler | $44.00 | $30.50 | 44.26% | 111.23% |
| Aug 09, 2022 | - | Leerink Partners | $70.00 | $27.52 | 154.36% | 236.05% |
| Jun 15, 2022 | - | Leerink Partners | $66.00 | $19.50 | 238.46% | 216.85% |
| Jun 14, 2022 | Edward Tenthoff | Piper Sandler | $37.00 | $19.50 | 89.74% | 77.63% |
The latest PureTech Health stock forecast, released on Aug 25, 2022 by Edward Tenthoff from Piper Sandler, set a price target of $44.00, which represents a 44.26% increase from the stock price at the time of the forecast ($30.50), and a 111.23% increase from PRTC last price ($20.83).
PureTech Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $20.83 | $20.83 | $20.83 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of PureTech Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to PureTech Health's last price of $20.83. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 25, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 09, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Jun 15, 2022 | SVB Leerink | Outperform | Outperform | Hold |
PureTech Health's last stock rating was published by Piper Sandler on Aug 25, 2022. The company gave PRTC a "Overweight" rating, the same as its previous rate.
PureTech Health Financial Forecast
PureTech Health Revenue Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | $143.63K | $7.50M | $6.00M |
| High Forecast | $143.63K | $7.50M | $6.00M |
| Low Forecast | $143.63K | $7.50M | $6.00M |
| # Analysts | 1 | 1 | 1 |
| Surprise % | - | - | - |
PureTech Health's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRTC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
PureTech Health EBITDA Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EBITDA | - | - | - |
| Avg Forecast | $-143.63K | $-7.50M | $-6.00M |
| High Forecast | $-143.63K | $-7.50M | $-6.00M |
| Low Forecast | $-143.63K | $-7.50M | $-6.00M |
| Surprise % | - | - | - |
undefined analysts predict PRTC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PureTech Health's previous annual EBITDA (undefined) of $NaN.
PureTech Health Net Income Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| Net Income | - | - | - |
| Avg Forecast | $415.65M | $-817.06M | $-876.38M |
| High Forecast | $415.65M | $-817.06M | $-876.38M |
| Low Forecast | $415.65M | $-817.06M | $-876.38M |
| Surprise % | - | - | - |
PureTech Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRTC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PureTech Health SG&A Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| SG&A | - | - | - |
| Avg Forecast | $1.20M | $62.80M | $50.24M |
| High Forecast | $1.20M | $62.80M | $50.24M |
| Low Forecast | $1.20M | $62.80M | $50.24M |
| Surprise % | - | - | - |
PureTech Health's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PRTC last annual SG&A of $NaN (undefined).
PureTech Health EPS Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EPS | - | - | - |
| Avg Forecast | $1.54 | $-3.03 | $-3.25 |
| High Forecast | $1.54 | $-3.03 | $-3.25 |
| Low Forecast | $1.54 | $-3.03 | $-3.25 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, PureTech Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRTC previous annual EPS of $NaN (undefined).
PureTech Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| OPT | Opthea | $4.21 | $14.00 | 232.54% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
| ACRV | Acrivon Therapeutics | $7.85 | $22.00 | 180.25% | Buy |
| PRTC | PureTech Health | $20.83 | $57.00 | 173.64% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| RZLT | Rezolute | $5.44 | $13.50 | 148.16% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| JANX | Janux Therapeutics | $55.87 | $61.20 | 9.54% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
PRTC Forecast FAQ
Is PureTech Health a good buy?
Yes, according to 2 Wall Street analysts, PureTech Health (PRTC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of PRTC's total ratings.
What is PRTC's price target?
PureTech Health (PRTC) average price target is $57 with a range of $44 to $70, implying a 173.64% from its last price of $20.83. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will PureTech Health stock go up soon?
According to Wall Street analysts' prediction for PRTC stock, the company can go up by 173.64% (from the last price of $20.83 to the average price target of $57), up by 236.05% based on the highest stock price target, and up by 111.23% based on the lowest stock price target.
Can PureTech Health stock reach $30?
PRTC's average twelve months analyst stock price target of $57 supports the claim that PureTech Health can reach $30 in the near future.
What are PureTech Health's analysts' financial forecasts?
PRTC's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $6M (high $6M, low $6M), average EBITDA is $-6M (high $-6M, low $-6M), average net income is $-876M (high $-876M, low $-876M), average SG&A $50.24M (high $50.24M, low $50.24M), and average EPS is $-3.25 (high $-3.25, low $-3.25).